Algeta Release: New Data and Analyses From the Phase 3 ALSYMPCA Trial of Xofigo® (Radium Ra 223 Dichloride) Injection to be Presented at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013

Published: Sep 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Algeta ASA (OSE:ALGETA), announced today that further analyses of data subsets from the phase III ALSYMPCA study of Xofigo(®) (radium Ra 223 dichloride) injection will be presented at the 2013 European Cancer Congress (ECCO/ESMO/ESTRO), 28 September- 1 October, in Amsterdam, The Netherlands.

Help employers find you! Check out all the jobs and post your resume.

Back to news